Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vyxeos (cytarabine/daunorubicin liposomal formulation)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jazz, Nippon Shinyaku

Drug class:

DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor

Related drugs:

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

liposomal cytarabine (0)

valacyclovir (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

idarubicin hydrochloride (16)

mitoxantrone (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

H-ferritin–nanocaged doxorubicin (0)

non-pegylated liposomal doxorubicin (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

liposomal cytarabine (0)

valacyclovir (0)

›

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
CEBPA mutation	Acute Myelogenous Leukemia	CEBPA mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
PHF6 mutation	Acute Myelogenous Leukemia	PHF6 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
FLT3 A848P + MLL-MLLT3 fusion	Acute Myelogenous Leukemia	FLT3 A848P + MLL-MLLT3 fusion	Acute Myelogenous Leukemia	ARO-002 + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials ARO-002 + cytarabine / daunorubicin liposomal formulation Sensitive : C3	ARO-002 + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials ARO-002 + cytarabine / daunorubicin liposomal formulation Sensitive : C3
Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia	Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3
KDM6A mutation	Acute Myelogenous Leukemia	KDM6A mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Sensitive : C4	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Sensitive : C4